Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1b Trial to Assess the Safety and Efficacy of ST316 in Participants With Familial Adenomatous Polyposis (FAP)

NCT07729371 is registered in ClinicalTrials.gov with Sapience Therapeutics as lead sponsor.

NCT NCT07729371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07729371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1b Trial to Assess the Safety and Efficacy of ST316 in Participants With Familial Adenomatous Polyposis (FAP)
Lead sponsor
Sapience Therapeutics
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 4, 2027
Completion date
December 31, 2029
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis (fap)